Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
Tango Therapeutics, Inc. President of R&D Crystal Adam reported an exercise-and-sale transaction in company stock. On June 1, 2026, she exercised 27,000 stock options at $5.20 per share and sold 27,000 common shares in open-market trades at weighted average prices of $22.25 and $23.06 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, she directly holds 142,743 shares of common stock and 341,040 stock options.
Tango Therapeutics, Inc. amendment reports that TCG Crossover II entities and Chen Yu together beneficially hold 11,597,737 shares of Common Stock, representing 8.1% of the class. The disclosure states this position includes 1,066,666 shares underlying pre-funded warrants exercisable within 60 days.
The filing cites a pool of 143,735,517 shares used for calculation, reflecting 142,668,851 shares outstanding as of February 26, 2026 plus the exercisable pre-funded warrants. It notes a Beneficial Ownership Limitation that caps exercises at 9.99%.
Tango Therapeutics, Inc. Schedule 13G/A reports that Nextech Crossover I SCSp and related reporting persons beneficially own 7,266,081 shares of common stock as of March 31, 2026. The filing states this represents 5.1% of the issuer's outstanding shares, based on 142,688,851 shares outstanding as of February 26, 2026. The cover rows show that Nextech Crossover I SCSp directly holds the shares, Nextech Crossover I GP S.a. r.l. is the general partner, and Ian Charoub, Costas Constantinides and Rocco Sgobbo have the power to direct voting and disposition of those securities. The Reporting Persons expressly disclaim status as a 'group.'
Woodline Partners reported beneficial ownership of 8,000,013 shares of Tango Therapeutics, Inc. common stock, representing 5.6% of the class. The filing states the percentage is calculated using 142,688,851 shares outstanding as of February 26, 2026. The ownership is held directly by Woodline Funds and Woodline Partners disclaims that this filing alone establishes beneficial ownership for Section 13 purposes.
Tango Therapeutics disclosure: RTW Investments, LP and Roderick Wong report shared beneficial ownership of 13,300,620 shares of Tango Therapeutics common stock, representing 9.3% of the class based on 142,688,851 shares outstanding as of February 26, 2026. The shares are held by RTW Funds and voting/dispositive power is shared; sole voting and sole dispositive power are reported as zero. The statement is filed on behalf of RTW Investments and Dr. Wong and is signed by Dr. Wong on May 15, 2026.
Tango Therapeutics reported first quarter 2026 results and highlighted progress in its oncology pipeline. The company ended March 31, 2026 with $379.8 million in cash, cash equivalents and marketable securities, which it expects will fund operations into 2028.
Collaboration revenue was $0 for the quarter, compared with $5.4 million a year earlier after the Gilead collaboration concluded. Research and development expenses were $33.5 million versus $36.4 million, while general and administrative expenses rose to $15.2 million from $11.5 million.
Net loss was $45.5 million, or $0.32 per share, compared with a net loss of $39.9 million, or $0.36 per share, in the prior-year period. The company reported encouraging early data from vopimetostat combination studies and outlined multiple 2026 clinical milestones. Two directors, Alexis Borisy and Kanishka Pothula, resigned without disagreements, and Sung Lee was appointed Lead Independent Director and chair of the Compensation Committee.
Tango Therapeutics, Inc. reported first-quarter 2026 results showing no collaboration revenue, compared with $5.4M a year earlier, after the earlier truncation of its Gilead research collaboration. Research and development expense was $33.5M, down from $36.4M, mainly from lower spend on deprioritized programs, while general and administrative expense rose to $15.2M from $11.5M on higher personnel and stock-based compensation.
The company recorded a net loss of $45.5M (net loss per share $0.32) versus $39.9M (net loss per share $0.36) a year ago. Cash, cash equivalents and marketable securities totaled $379.8M as of March 31, 2026, and management expects this to fund operations into 2028.
During the quarter, Tango raised $64.4M in gross proceeds via its at-the-market stock offering, issuing 5,148,151 shares, and also generated $17.6M from stock option exercises. The company is prioritizing its MTAP-deleted selective PRMT5 pipeline, advancing vopimetostat and TNG456, while deprioritizing TNG260 and TNG961.
Tango Therapeutics reports a Schedule 13G/A showing Adage Capital and affiliated reporting persons beneficially own 12,809,485 shares of Common Stock, equal to 8.98% of the class. The percentage is calculated using 142,688,851 shares outstanding as of February 26, 2026.
The statement attributes shared voting and dispositive power of 12,809,485 shares to Adage Capital Management, L.P., with reporting by Robert Atchinson and Phillip Gross. The filing is signed on May 13, 2026.
Farallon Capital filed Amendment No. 4 reporting its beneficial ownership in Tango Therapeutics, Inc. The filing states the Farallon Funds hold an aggregate of 9,097,411 Shares and 2,159,792 Pre-Funded Common Stock Purchase Warrants, each exercisable for one Share. The filing says the Warrants are subject to a Beneficial Ownership Limitation of 9.99% and that the Reporting Persons have assumed all Warrants are exercisable within 60 days for the purpose of computing beneficial ownership. The filing lists the Farallon funds, affiliated general partners, and individual Farallon managers and provides per-entity ownership counts and shared voting/dispositive power figures.
Tango Therapeutics, Inc. entered into a Separation Agreement and Release with former Chief Financial Officer Daniella Beckman on May 7, 2026, following the Board’s earlier decision that she would cease serving as CFO, principal accounting officer and principal financial officer effective April 15, 2026.
Under the agreement and her employment contract, Ms. Beckman will receive 12 months of severance pay at her current base salary, paid in installments, plus reimbursement of monthly COBRA premiums for up to 12 months. The company will also accelerate the vesting of her outstanding stock options and restricted stock units to reflect an additional 24 months of continued service from her May 1, 2026 employment end date and extend the post-termination stock option exercise period through August 31, 2026, in exchange for her signing a general release in favor of the company.